LXEO Head of Research Dr. Adler departs; transition agreement through July 31, 2026

Lexeo Therapeutics, Inc.

Dr. Adler stepped down as Head of Research effective February 1, 2026; will provide advisory services through July 31, 2026 or earlier termination.
Under transition agreement, Dr. Adler will receive up to $62,500 in monthly installments; service-vesting equity continues to vest during transition period.
Option exercise period extended to six months after transition end; additional $1,000 lump sum possible upon execution of supplemental release.
Transition agreement includes customary release of claims, non-disparagement, and cooperation provisions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.